Guidelines on the use of 14-3-3 protein for diagnosis of CJD

Sporadic CJD is rare and difficult to diagnose. The American Academy of Neurology just released guidelines on the use of CSF protein 14-3-3 to diagnose the disease. They found in suspected patients (rapidly progressive dementia), the assay had a sensitivity and specificity of 92% and 80% respectively, which can help improve the certainty of diagnosis is patients with suspected disease (abstract).

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment